Craft

Theriva Biologics

Stock Price

$1.5

2024-10-29

Market Capitalization

$3.3 M

2024-10-29

Theriva Biologics Summary

Company Summary

Overview
Theriva Biologics (formerly known as Synthetic Biologics) is a clinical company that produces oncolytic virus therapeutics. It develops the Albumin Shield technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration.
Type
Public
Status
Active
Founded
2001
HQ
Rockville, MD, US | view all locations
Website
https://therivabio.com/
Cybersecurity rating
Sectors

Key People

  • Jeffrey J. Kraws, Chairman

    • Steven Shallcross

      Steven Shallcross, Chief Executive Officer, Chief Financial Officer, Director

    • Manel Cascallo

      Manel Cascallo, General Director, EU Subsidiary

    • Jeffrey Wolf, Director

      LocationsView all

      2 locations detected

      • Rockville, MD HQ

        United States

        9605 Medical Center Dr. Suite 270

      • Barcelona, CT

        Spain

        Carrer Torrent de Can Ninou, naus 5-6

      Theriva Biologics Financials

      Summary Financials

      Net income (Q3, 2024)
      ($7.7M)
      Cash (Q3, 2024)
      $16.4M
      EBIT (Q3, 2024)
      ($7.9M)
      Enterprise value
      ($12.0M)

      Footer menu